Funding for this research was provided by:
Horizon 2020 (642889 MEDICIS-PROMED, 654002 ENSAR2)
Text and Data Mining valid from 2019-06-11
Received: 8 March 2019
Accepted: 28 May 2019
First Online: 11 June 2019
Ethics approval and consent to participate
: All animal experiments in the present study were conducted according to the Swiss federal law on animal experimentation under the authorization number VD-2993. The present study does not include any experiment performed on human subjects.
: Not applicable. The present study does not contain any individual person’s data in any form.
: MS receives royalties from sales of the OLINDA/EXM software. GC has received grants, research support or is co-investigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance, and Kite. GC has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx. GC holds patents around TEM1 antibodies. GC is receiving royalties from Penn regarding technology licensed to Novartis.